A photo of Alexander Vinks.

Director, Division of Clinical Pharmacology

Scientific Director, Pharmacy Research, Research in Patient Services

Professor, UC Department of PediatricsAdjunct Professor of Pharmacology

513-636-0159

513-636-0168

Biography & Affiliation

Biography

Sander Vinks, PharmD, PhD, FCP, is a professor of pediatrics and pharmacology at the University of Cincinnati, College of Medicine. He is the director of the Division of Clinical Pharmacology, and serves as director of the Pediatric Clinical and Developmental Pharmacology NIH T32 training program since 2011. He is co-director of Cincinnati Children’s Genetic Pharmacology Service, and scientific director for pharmacy research in the Division of Patient Services. He also directs the Laboratory of Applied Pharmacokinetics and Pharmacogenetics (LAPP) and a multidisciplinary Pharmacometrics Core. Dr. Vinks also serves as an advisor on an FDA pediatric sub-committee.

Dr. Vinks is the past president of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He serves on the Board of Regents of the American College of Clinical Pharmacology and is chair of the Clinical Pharmacology and Translational Research Committee of the American Association of Pharmaceutical Scientists. He has served as the principal investigator of the former NICHD Pediatric Research Unit at Cincinnati Children’s Hospital Medical Center.

His major research interests include personalized and precision medicine, pharmacokinetic-pharmacodynamic (PK/PD) modeling, physiologically based pharmacokinetics (PBPK), pharmacogenetics/genomics (PG) and the application of genomic, population and simulation approaches (pharmacometrics) to pediatric trial design and therapeutic drug management.

Dr. Vinks has presented his research as an invited speaker in 220 national and international conferences, has published over 140 peer reviewed manuscripts and 18 book chapters and has presented more than 150 abstracts. He is associate editor of Clinical Pharmacology & Therapeutics. Dr. Vinks is both board certified in clinical pharmacology and toxicology and is a fellow of the American College of Clinical Pharmacology.

Academic Affiliation

Professor, UC Department of PediatricsAdjunct Professor of Pharmacology

Departments

Clinical Pharmacology, Reproductive Sciences, Pharmacy

Science Blog

Personalized Medicine through Modelinformed Precision Dosing

Personalized Medicine through Model-informed Precision Dosing

Alexander (Sander) A. Vinks, PharmD, PhD, FCP7/1/2019

Genomics Ushers in Era of Personalized Medicine

Genomics Ushers in Era of Personalized Medicine

Alexander (Sander) A. Vinks, PharmD, PhD, FCP6/30/2019

Education

Certification: American Board of Clinical Pharmacology, 2001.

PhD: Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.

PharmD: Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986.

MS: Pharmacology, University of Toronto, Toronto Canada, 1983.

MS: Pharmacy, Leiden University, Leiden, The Netherlands, 1981.

Publications

Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. American Journal of Hematology. 2019; 94:871-879.

Recommendations for the design of therapeutic trials for neonatal seizures. Soul, JS; Pressler, R; Allen, M; Boylan, G; Rabe, H; Portman, R; Hardy, P; Zohar, S; Romero, K; Tseng, B; et al. Pediatric Research. 2019; 85:943-954.

Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery. Mizuno, T; Gist, KM; Gao, Z; Wempe, MF; Alten, J; Cooper, DS; Goldstein, SL; Vinks, AA. Clinical Pharmacokinetics. 2019; 58:793-803.

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Brunet, M; van Gelder, T; Asberg, A; Haufroid, V; Hesselink, DA; Langman, L; Lemaitre, F; Marquet, P; Seger, C; Shipkova, M; et al. Therapeutic Drug Monitoring. 2019; 41:261-307.

Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Leino, AD; King, EC; Jiang, W; Vinks, AA; Klawitter, J; Christians, U; Woodle, ES; Alloway, RR; Rohan, JM. American Journal of Transplantation. 2019; 19:1410-1420.

Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. Ramsey, LB; Mizuno, T; Vinks, AA; O'Brien, MM. Pediatric Blood and Cancer. 2019; 66.

A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition. Emoto, C; Johnson, TN; Hahn, D; Christians, U; Alloway, RR; Vinks, AA; Fukuda, T. CPT: Pharmacometrics and Systems Pharmacology. 2019; 8:273-284.

Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study. Hahn, D; Emoto, C; Euteneuer, JC; Mizuno, T; Vinks, AA; Fukuda, T. Clinical Pharmacology and Therapeutics. 2019; 105:761-768.

From Molecule to Patient and Ways to Get the Dose Precisely Right. Vinks, AA. Clinical Pharmacology and Therapeutics. 2019; 105:534-537.

Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy. Euteneuer, JC; Kamatkar, S; Fukuda, T; Vinks, AA; Akinbi, HT. Journal of Clinical Pharmacology. 2019; 59:168-176.